Cardiol Therapeutics (TSX:CRDL) EV-to-Revenue : (As of Dec. 14, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Cardiol Therapeutics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Cardiol Therapeutics's enterprise value is C$138.51 Mil. Cardiol Therapeutics's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 was C$0.00 Mil. Therefore, Cardiol Therapeutics's EV-to-Revenue for today is .

The historical rank and industry rank for Cardiol Therapeutics's EV-to-Revenue or its related term are showing as below:

During the past 7 years, the highest EV-to-Revenue of Cardiol Therapeutics was 2617.12. The lowest was -452.19. And the median was 347.34.

TSX:CRDL's EV-to-Revenue is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 2.495
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-12-14), Cardiol Therapeutics's stock price is C$1.89. Cardiol Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was C$0.00. Therefore, Cardiol Therapeutics's PS Ratio for today is .

Cardiol Therapeutics EV-to-Revenue Historical Data

The historical data trend for Cardiol Therapeutics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cardiol Therapeutics EV-to-Revenue Chart

Cardiol Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

765.82

Cardiol Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EV-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Cardiol Therapeutics's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Cardiol Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cardiol Therapeutics's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cardiol Therapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Cardiol Therapeutics's EV-to-Revenue falls into.

Cardiol Therapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Cardiol Therapeutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	138.511	/	0
	=

Cardiol Therapeutics's current Enterprise Value is C$138.51 Mil.
Cardiol Therapeutics's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00 Mil.

Cardiol Therapeutics (TSX:CRDL) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Cardiol Therapeutics's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	1.89	/	0
	=

Cardiol Therapeutics's share price for today is C$1.89.
Cardiol Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00.

Cardiol Therapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Cardiol Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Cardiol Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cardiol Therapeutics Inc (TSX:CRDL) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

CRDL:USA CT9:Germany

Address

2265 Upper Middle Road East, Suite 602, Oakville, ON, CAN, L6H 0G5

Website

https://www.cardiolrx.com

Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

Executives

Guillermo Torre	Senior Officer
Colin George Stott	Director
Deborah Brown	Director
Peter Pekos	Director
Iain Chalmers	Director
David Elsley	Director, Senior Officer
Eldon Smith	Director
Christopher James Waddick	Director, Senior Officer